New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs
- 12 February 2010
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 46 (11) , 1842-1844
Abstract
Reduction of anticancer prodrugs such as ctc-[PtCl2(CH3CO2)2(NH3)(Am)] can yield three products in addition to the expected cis-[PtCl2(NH3)(Am)], by the loss of two axial ligands, one axial and one equatorial ligand, or two equatorial ligands.Keywords
This publication has 18 references indexed in Scilit:
- Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancerGynecologic Oncology, 2009
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Basis for Design and Development of Platinum(IV) Anticancer ComplexesJournal of Medicinal Chemistry, 2007
- Platinum(IV) antitumour compounds: their bioinorganic chemistryCoordination Chemistry Reviews, 2002
- Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions †J. Chem. Soc., Dalton Trans., 2000
- Reduction of the anti-cancer drug analogue cis,trans,cis-[PtCl2(OCOCH3)2(NH3)2] by L-cysteine and L-methionine and its crystal structure †J. Chem. Soc., Dalton Trans., 1999
- Reduction and Anticancer Activity of Platinum(IV) ComplexesInorganic Chemistry, 1998
- Biotransformation of the platinum drug JM216 following oral administration to cancer patientsCancer Chemotherapy and Pharmacology, 1996
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969
- Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum ElectrodeNature, 1965